M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
Abstract Tumor associated macrophages (TAMs) play a critical role in biology of various cancers, including breast cancer. In the current study, we defined “M1” macrophage and “M1”/“M2” ratio by transcriptomic signatures using xCell. We investigated the association between high level of “M1” macropha...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/318de2ecfd984b2d809073b5c0d913ba |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:318de2ecfd984b2d809073b5c0d913ba |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:318de2ecfd984b2d809073b5c0d913ba2021-12-02T18:37:07ZM1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer10.1038/s41598-020-73624-w2045-2322https://doaj.org/article/318de2ecfd984b2d809073b5c0d913ba2020-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-73624-whttps://doaj.org/toc/2045-2322Abstract Tumor associated macrophages (TAMs) play a critical role in biology of various cancers, including breast cancer. In the current study, we defined “M1” macrophage and “M1”/“M2” ratio by transcriptomic signatures using xCell. We investigated the association between high level of “M1” macrophage or “M1”/“M2” ratio and the tumor immune microenvironment by analyzing the transcriptome of publicly available cohorts, TCGA and METABRIC. We found that “M1” high tumors were not associated with prolonged survival compared with “M1” low tumors, or with the response to neoadjuvant chemotherapy. “M1” high tumors were associated with clinically aggressive features and “M1” high tumors enriched the cell proliferation and cell cycle related gene sets in GSEA. At the same time, “M1” high tumors were associated with high immune activity and favorable tumor immune microenvironment, as well as high expression of immune check point molecules. Strikingly, all these results were mirrored in “M1”/“M2” ratio high tumors. In conclusion, transcriptomically defined “M1” or “M1”/“M2” high tumors were associated with aggressive cancer biology and favorable tumor immune microenvironment but not with survival benefit, which resembled only part of their conventional clinical characteristics.Masanori OshiYoshihisa TokumaruMariko AsaokaLi YanVikas SatyanandaRyusei MatsuyamaNobuhisa MatsuhashiManabu FutamuraTakashi IshikawaKazuhiro YoshidaItaru EndoKazuaki TakabeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-12 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Masanori Oshi Yoshihisa Tokumaru Mariko Asaoka Li Yan Vikas Satyananda Ryusei Matsuyama Nobuhisa Matsuhashi Manabu Futamura Takashi Ishikawa Kazuhiro Yoshida Itaru Endo Kazuaki Takabe M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer |
| description |
Abstract Tumor associated macrophages (TAMs) play a critical role in biology of various cancers, including breast cancer. In the current study, we defined “M1” macrophage and “M1”/“M2” ratio by transcriptomic signatures using xCell. We investigated the association between high level of “M1” macrophage or “M1”/“M2” ratio and the tumor immune microenvironment by analyzing the transcriptome of publicly available cohorts, TCGA and METABRIC. We found that “M1” high tumors were not associated with prolonged survival compared with “M1” low tumors, or with the response to neoadjuvant chemotherapy. “M1” high tumors were associated with clinically aggressive features and “M1” high tumors enriched the cell proliferation and cell cycle related gene sets in GSEA. At the same time, “M1” high tumors were associated with high immune activity and favorable tumor immune microenvironment, as well as high expression of immune check point molecules. Strikingly, all these results were mirrored in “M1”/“M2” ratio high tumors. In conclusion, transcriptomically defined “M1” or “M1”/“M2” high tumors were associated with aggressive cancer biology and favorable tumor immune microenvironment but not with survival benefit, which resembled only part of their conventional clinical characteristics. |
| format |
article |
| author |
Masanori Oshi Yoshihisa Tokumaru Mariko Asaoka Li Yan Vikas Satyananda Ryusei Matsuyama Nobuhisa Matsuhashi Manabu Futamura Takashi Ishikawa Kazuhiro Yoshida Itaru Endo Kazuaki Takabe |
| author_facet |
Masanori Oshi Yoshihisa Tokumaru Mariko Asaoka Li Yan Vikas Satyananda Ryusei Matsuyama Nobuhisa Matsuhashi Manabu Futamura Takashi Ishikawa Kazuhiro Yoshida Itaru Endo Kazuaki Takabe |
| author_sort |
Masanori Oshi |
| title |
M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer |
| title_short |
M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer |
| title_full |
M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer |
| title_fullStr |
M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer |
| title_full_unstemmed |
M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer |
| title_sort |
m1 macrophage and m1/m2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/318de2ecfd984b2d809073b5c0d913ba |
| work_keys_str_mv |
AT masanorioshi m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer AT yoshihisatokumaru m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer AT marikoasaoka m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer AT liyan m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer AT vikassatyananda m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer AT ryuseimatsuyama m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer AT nobuhisamatsuhashi m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer AT manabufutamura m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer AT takashiishikawa m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer AT kazuhiroyoshida m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer AT itaruendo m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer AT kazuakitakabe m1macrophageandm1m2ratiodefinedbytranscriptomicsignaturesresembleonlypartoftheirconventionalclinicalcharacteristicsinbreastcancer |
| _version_ |
1718377789114023936 |